CALGARY, ALBERTA - August 21, 2025 (NEWMEDIAWIRE) - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) ("Voyageur" or the "Company"), a radiology contrast media company focused on vertical ...
Positive feedback received after completion of CDC tests on 24 subjects All key product performance milestones met or exceeded expectations Voyageur believes it is now a player in the contrast media ...
Voyageur Completes Human Testing of Barium Contrast Products and Prepares for Canadian Market Launch
Calgary, Alberta, Canada – April 1, 2025 –TheNewswire -Voyageur Pharmaceuticals Ltd. (VM:CA) (OTC Pink:VYYRF) ("Voyageur" or the "Company") is pleased to announce the successful completion of a key ...
Bracco Diagnostics announced that the Food and Drug Administration (FDA) has approved E-Z-HD (barium sulfate) for oral suspension for use in double-contrast radiographic examinations of the esophagus, ...
CALGARY, Alberta, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Voyageur Pharmaceuticals Ltd. (TSX.V:VM, USA:VYYRF) (the “Company” or “Voyageur”) is pleased to announce the fully-integrated iodine business ...
CALGARY, AB - November 7, 2025 (NEWMEDIAWIRE) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC: VYYRF) (the "Company" or "Voyageur"), a Canadian developer of pharmaceutical-grade barium and iodine for ...
Bracco Diagnostics announced that the FDA has approved a New Drug Application (NDA) for READI-CAT 2 and READI-CAT 2 SMOOTHIE (barium sulfate) oral suspension for use in computed tomography (CT) of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback